Literature DB >> 25977137

ICSH guidelines for the standardization of bone marrow immunohistochemistry.

E E Torlakovic1, R K Brynes2, E Hyjek3, S-H Lee4, H Kreipe5, M Kremer6, R McKenna7, Y Sadahira8, A Tzankov9, M Reis10, A Porwit1,11.   

Abstract

Bone marrow (BM) tissue biopsy evaluation, including trephine biopsy and clot section, is an integral part of BM investigation and is often followed by ancillary studies, in particular immunohistochemistry (IHC). IHC provides in situ coupling of morphological assessment and immunophenotype. The number of different IHC tests that can be applied to BM trephine biopsies and the number of indications for IHC testing is increasing concurrently with the development of flow cytometry and molecular diagnostic methods. An international Working Party for the Standardization of Bone Marrow IHC was formed by the International Council for Standardization in Hematology (ICSH) to prepare a set of guidelines for the standardization of BM IHC based on currently available published evidence and modern understanding of quality assurance principles as applied to IHC in general. The guidelines were discussed at the ICSH General Assemblies and reviewed by an international panel of experts to achieve further consensus and represent further development of the previously published ICSH guidelines for the standardization of BM specimens handling and reports.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Standardization; bone marrow; immunohistochemistry; trephine biopsy

Mesh:

Year:  2015        PMID: 25977137     DOI: 10.1111/ijlh.12365

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  7 in total

1.  Defective WNT signaling associates with bone marrow fibrosis-a cross-sectional cohort study in a family with WNT1 osteoporosis.

Authors:  R E Mäkitie; R Niinimäki; S Kakko; T Honkanen; P E Kovanen; O Mäkitie
Journal:  Osteoporos Int       Date:  2017-11-16       Impact factor: 4.507

Review 2.  Systematic evaluation of immune regulation and modulation.

Authors:  David F Stroncek; Lisa H Butterfield; Michael A Cannarile; Madhav V Dhodapkar; Tim F Greten; Jean Charles Grivel; David R Kaufman; Heidi H Kong; Firouzeh Korangy; Peter P Lee; Francesco Marincola; Sergio Rutella; Janet C Siebert; Giorgio Trinchieri; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

3.  Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

Authors:  Michael Medinger; Alexandar Tzankov; Magdalena M Brune; Georg Stüssi; Pontus Lundberg; Visar Vela; Dominik Heim; Markus G Manz; Eugenia Haralambieva; Thomas Pabst; Yara Banz; Mario Bargetzi; Rainer Grobholz; Martin Fehr; Sergio Cogliatti; Gert J Ossenkoppele; Bob Löwenberg; Christina Biaggi Rudolf; Qiyu Li; Jakob Passweg; Luca Mazzuchelli
Journal:  Ann Hematol       Date:  2021-03-02       Impact factor: 3.673

4.  Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.

Authors:  Duanfeng Jiang; Yanan Zhang; Shiming Tan; Jing Liu; Xin Li; Congming Zhang
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

Review 5.  International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

Authors:  Luciano J Costa; Benjamin A Derman; Susan Bal; Surbhi Sidana; Saurabh Chhabra; Rebecca Silbermann; Jing C Ye; Gordon Cook; Robert F Cornell; Sarah A Holstein; Qian Shi; James Omel; Natalie S Callander; Wee Joo Chng; Vania Hungria; Angelo Maiolino; Edward Stadtmauer; Sergio Giralt; Marcelo Pasquini; Andrzej J Jakubowiak; Gareth J Morgan; Amrita Krishnan; Graham H Jackson; Mohamad Mohty; Maria Victoria Mateos; Meletious A Dimopoulos; Thierry Facon; Andrew Spencer; Jesus San Miguel; Parameswaran Hari; Saad Z Usmani; Salomon Manier; Phillip McCarthy; Shaji Kumar; Francesca Gay; Bruno Paiva
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528

Review 6.  Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.

Authors:  Rosemarie Tremblay-LeMay; Nasrin Rastgoo; Hong Chang
Journal:  J Hematol Oncol       Date:  2018-03-27       Impact factor: 17.388

7.  The role of the pathology department in the preanalytical phase of molecular analyses.

Authors:  Sergiu Susman; Ioana Berindan-Neagoe; Bobe Petrushev; Radu Pirlog; Ioan-Stefan Florian; Carmen-Mihaela Mihu; Cristian Berce; Lucian Craciun; Ravnit Grewal; Ciprian Tomuleasa
Journal:  Cancer Manag Res       Date:  2018-04-12       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.